BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 34599863)

  • 1. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
    Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
    Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.
    Li D; Ding L; Ran W; Huang Y; Li G; Wang C; Xiao Y; Wang X; Lin D; Xing X
    Thorac Cancer; 2020 Sep; 11(9):2580-2589. PubMed ID: 32729257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
    Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
    Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
    Mascarenhas E; Gelatti AC; Araújo LH; Baldotto C; Mathias C; Zukin M; Werutsky G; Pacheco P; Gomes R; de Castro G; Cordeiro de Lima VC
    Thorac Cancer; 2021 Mar; 12(5):580-587. PubMed ID: 33314759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.
    Araujo LH; Lammers PE; Matthews-Smith V; Eisenberg R; Gonzalez A; Schwartz AG; Timmers C; Shilo K; Zhao W; Natarajan TG; Zhang J; Yilmaz AS; Liu T; Coombes K; Carbone DP
    J Thorac Oncol; 2015 Oct; 10(10):1430-6. PubMed ID: 26301800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
    Hu W; Liu Y; Chen J
    Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
    Liu L; Liu J; Shao D; Deng Q; Tang H; Liu Z; Chen X; Guo F; Lin Y; Mao M; Kristiansen K; Ye M; He J
    Cancer Sci; 2017 Dec; 108(12):2487-2494. PubMed ID: 28949084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
    Grosse A; Grosse C; Rechsteiner M; Soltermann A
    Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer.
    Si X; Pan R; Ma S; Li L; Liang L; Zhang P; Chu Y; Wang H; Wang M; Zhang X; Zhang L
    Thorac Cancer; 2021 Feb; 12(3):357-363. PubMed ID: 33300283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.